Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Multiple myeloma musings: highlights from 2018 data

Joshua Richter • 16 Jan 2019
ASH 2018
Multiple Myeloma Antibodies CAR-T Daratumumab Dexamethasone Lenalidomide
LEGEND-2 MAIA

Joshua Richter, MD, of Mount Sinai Medical Center, New York, NY, gives us his take on the key highlights in multiple myeloma (MM) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Dr Richter discusses the up-and-coming new tools being investigated in clinical trials, and also reveals the use of old tools in novel ways, notably in the MAIA study (NCT02252172).

More from Joshua Richter

1:33
Updates from the LINKER-MM1 study: linvoseltamab in R/R multiple myeloma
Joshua Richter • 27 Sep 2023
1:14
Prevention & monitoring of infections in patients with multiple myeloma treated with immunotherapies
Joshua Richter • 27 Sep 2023
1:44
Matching-adjusted indirect comparison of Isa-Kd versus Dara-Rd in relapsed multiple myeloma
Joshua Richter • 27 Sep 2023
1:45
The value of teclistamab in R/R myeloma & strategies to mitigate toxicities
Joshua Richter • 27 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals